






































First-line HIV treatment outcomes following the
introduction of integrase inhibitors in
UK guidelines
Kate El Bouzidia,b, Sophie Josea, Andrew N. Phillipsa, Anton Pozniakc,
Andrew Ustianowskid, Mark Gompelse, Alan Winstonf, Ab Schaapg,
David T. Dunna, Caroline A. Sabina, on behalf of the UK CHIC Study
Objective: To investigate the characteristics and outcomes of people who initiated
different antiretroviral therapy (ART) regimens during the era of integrase strand transfer
inhibitors (INSTIs).
Design: UK-based observational cohort study.
Methods: UK Collaborative HIV Cohort study participants were included if they had
started ART between 1 January 2012 and 30 June 2017. Virological failure was defined
as the first of two consecutive plasma HIV RNA more than 50 copies/ml, at least 6
months after starting ART. Follow-up was censored at ART discontinuation, class switch
or death. The risk of virological failure among those on INSTI, protease inhibitor or
nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens was compared using
Kaplan–Meier and Cox regression methods.
Results: Of 12 585 participants, 45.6% started a NNRTI, 29.0% a protease inhibitor and
25.4% an INSTI regimen. Over a median follow-up of 20.3 months (interquartile range
7.9–38.9), 7.5% of participants experienced virological failure. Compared with those
starting an NNRTI regimen, people receiving INSTIs or protease inhibitors were more
likely to experience virological failure: INSTI group adjusted hazard ratio 1.52, 95%
confidence interval 1.19–1.95, P¼0.0009; protease inhibitor group adjusted hazard
ratio 2.70, 95% confidence interval 2.27–3.21, P less than 0.0001, likelihood ratio test
P less than 0.0001.
Conclusion: First-line INSTI regimens were associated with a lower risk of virological
failure than protease inhibitor regimens but both groups were more likely to experience
virological failure than those initiating treatment with a NNRTI. There is likely to be
residual channelling bias resulting from selected use of INSTIs and protease
inhibitors in specific clinical contexts, including in those with a perceived risk of poor
adherence.
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Introduction
Integrase strand transfer inhibitors (INSTIs) form the
newest class of antiretroviral agents to be incorporated
into the standard of care for treatment-naive people living
with HIV in the United Kingdom. The British HIV
Association (BHIVA) guidelines included raltegravir as a
preferred first-line agent in 2012, followed by elvite-
gravir-cobicistat in 2013 and dolutegravir in 2015 [1,2].
The INSTI class has performed well when compared
with other third agents in randomized controlled trials
(RCTs) of first-line antiretroviral therapy (ART). The
STARTMRK trial randomized ART-naive participants
to receive either raltegravir or the nonnucleoside reverse
transcriptase inhibitor (NNRTI) efavirenz, with a
nucleos(t)ide reverse transcriptase inhibitor (NRTI)
backbone of tenofovir and emtricitabine. Raltegravir
was found to be noninferior to efavirenz at achieving viral
suppression at 96 weeks with fewer adverse effects in the
raltegravir arm (47 and 78%, P< 0.001) [3]. Raltegravir
was then compared with the boosted protease inhibitors
darunavir and atazanavir, with a tenofovir-emtricitabine
backbone in the phase III open label study ACTG A5257
[4]. The incidence of virological failure was demonstrated
to be equivalent for all comparisons, though the
atazanavir arm had more discontinuations due to poor
tolerability. The next INSTI to become available was
elvitegravir, coadministered with the pharmaco-enhanc-
ing agent, cobicistat, and this was shown to be noninferior
to efavirenz [5] and to atazanavir [6,7]. Dolutegravir, a
next-generation INSTI, was found to be superior to
efavirenz in ART-naive participants in two RCTs:
SPRING-1, a phase IIb dose-ranging study in which
the dolutegravir 50 mg once daily arm had 88% viral
suppression at 96 weeks compared with 72% of the
efavirenz arm, and SINGLE, a phase III study in which
viral suppression was achieved in 88 and 81% at 48 weeks,
respectively [8,9]. The difference in primary endpoint in
the latter study was maintained out to week 144 (with
viral suppression rates of 71 and 63% in the two groups,
respectively), although interestingly the proportions with
virological nonresponse at this time, as determined by the
US Food and Drug Administration snapshot algorithm,
demonstrated a small benefit to efavirenz (10 vs. 7%,
respectively) [10]. Two further trials [11,12] demon-
strated noninferiority of dolutegravir in comparison to
efavirenz. Dolutegravir was also shown to be noninferior
to atazanavir in the ARIA study [13] and to darunavir in
the FLAMINGO study [14].
In addition to the antiretroviral efficacy demonstrated in
clinical trials, the choice of regimen may depend on
multiple factors that influence patient and physician
preferences. These may include demands of the regimen,
tolerability, toxicity, coexisting medical conditions and
perceived likelihood of poor adherence. Economic
considerations and accessibility are also important. Many
of the older antiretroviral agents are due to come off
patent in the next few years, with cheaper generic
versions becoming increasingly available [15]. These
factors that affect regimen selection may also be related to
the effectiveness of ART. Therefore, real-world compar-
isons of ART classes may yield different results from those
observed in clinical trial settings. The aim of this study
was to investigate whether first-line ART regimens
containing INSTIs are associated with a different risk of
virological failure compared with other standard treat-
ment regimens in a UK cohort of adults living with HIV.
The study period of 2012–2017 encompasses the
introduction of INSTIs as preferred options for first-
line treatment in BHIVA guidelines and their widespread
use in the United Kingdom.
Methods
Prospectively collected data from the UK Collaborative
HIV Cohort (UK CHIC) study were analysed to
compare virological responses among first-line HIV
treatment regimens. UK CHIC is an observational study
involving 20 collaborating clinical centres, which began
in 2001 with the aim of investigating clinical outcomes
and treatment responses in the United Kingdom [16,17].
UK CHIC participants were included if they had initiated
their first ART regimen between 1 January 2012 and 30
June 2017, allowing the potential for at least 6 months of
follow-up to the end of 2017. Eligible ART regimens
contained one INSTI, one boosted protease inhibitor or
one NNRTI; but not more than one of these three classes.
Participants were excluded if they had an undetectable
viral load (HIV RNA< 50 copies/ml) at ART initiation.
Statistical analysis
Categorical variables were compared by Chi-square test.
Continuous variables with normal distributions were
compared by analysis of variance (ANOVA) and those
with nonnormal distributions by Kruskal–Wallis test.
The main exposure of interest was the treatment group:
INSTI, protease inhibitor or NNRTI. The NNRTI
group was used as the reference for comparisons as this has
historically been the default class of third agent
recommended in the BHIVA guidelines [18–20]. The
primary outcome was virological failure, which was
defined as the first of two consecutive HIV RNA
measurements more than 50 copies/ml, at least 6 months
after ART initiation. Follow-up was censored on the date
of a regimen change, date of death, 6 months after the last
clinic visit or the administrative censoring date (31
December 2017), whichever was earliest. A regimen
change was stopping the class that defined the treatment
group (but participants could change agents within a
class), or starting an agent from a different class.
Participants were considered lost to follow-up on the
date of the last clinic visit if this occurred more than 1 year
before the administrative censoring date. Cumulative risk
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of virological failure was estimated by Kaplan–Meier
methods, stratified by treatment group and compared
with the log-rank test. Cox regression was used to
estimate hazard ratios (HRs) to test the association
between treatment group and virological failure, and to
identify other risk factors for virological failure. An
intention-to-treat analysis was performed in which a
regimen change did not result in censoring follow-up.
Sensitivity analysis was performed to assess the robustness
of the findings to the choice of virological failure
definition (e.g. single or consecutive HIV RNA
measurements of >50 copies/ml, >200 copies/ml and
>1000 copies/ml). All statistical analysis was undertaken
with SAS software version 9.4 (SAS Institute, Cary, North
Carolina, USA).
Ethical approval
The UK CHIC study has ethical approval from the West
Midlands multicentre research ethics committee (refer-
ence MREC/00/7/47) and by local ethics committees.
This sub-study was approved by the UK CHIC steering
committee and by the London School of Hygiene &
Tropical Medicine ethics committee (reference 13628).
Results
Study population
The UK CHIC study dataset up to the end of 2017
included 73 988 individuals, of whom 15 011 started
ART between 1 January 2012 and 30 June 2017 (Fig. 1).
Two thousand, four hundred and twenty-six people were
excluded because they had an undetectable viral load at
ART initiation or had received an ART regimen that
either did not contain a NNRTI, protease inhibitor or
INSTI, or contained more than one of these classes. The
remaining 12 585 participants were eligible for inclusion
in the study, of whom 5744 (45.6%) received a regimen
containing a NNRTI, 3648 (29.0%) received a protease
inhibitor and 3193 (25.4%) received an INSTI.
The baseline characteristics of the study participants are
shown in Table 1. The majority were men (80%), white
ethnicity (56%), with a mean age of 37 and median CD4þ
cell count of 379 cells/ml at ART initiation. Factors
independently associated with treatment group were sex,
ethnicity, HIVacquisition risk group, baseline CD4þ cell
count, viral load, year of ART initiation and NRTI
backbone. In the years 2012–2013, 60.6% (3037/5010)
of participants starting ART received an NNRTI; this
proportion fell to 24.8% (653/2632) in 2016/2017.
There was also a decrease in the proportion that received
protease inhibitors, from 33.7% (1685/5010) in 2012/
2013 to 24.2% (638/2632) in 2016/2017. This corre-
sponded with the rollout of INSTIs and a rapid rise in
their use as first-line agents, from 5.8% (288/5010) to
51.0% (1341/2632) in the same period. Regarding
individual ART agents, the largest treatment group,
NNRTI, mainly consisted of people starting efavirenz
(4395/5744, 76.5%) or rilpivirine (1071, 18.7%), with a
minority receiving nevirapine (247, 4.3%), etravirine (28,
0.5%) or another NNRTI (3, 0.05%). Of participants
receiving a protease inhibitor, 2480 (68.0%) commenced
darunavir and 1025 (28.1%) atazanavir. The older
protease inhibitors, lopinavir (136, 3.7%), fosamprenavir
(5, 0.1%) and saquinavir (2, 0.05%) were also prescribed
in a few cases. Among those receiving an INSTI, 1886
(59.1%) received raltegravir, 935 (29.3%) dolutegravir
and 372 (11.7%) elvitegravir.
Treatment outcomes and risk factors for
virological failure
The cohort was followed for a total of 26 067 person-
years, during which time 7.5% (947/12 585) experienced
virological failure. The median follow-up time on ART
was 20.3 months, interquartile range 7.9–38.9 [NNRTI
group: 28.3 months (10.0–48.8), protease inhibitor
group: 12.7 months (6.0–33.5), INSTI group: 18.4
months (9.0–28.9), P< 0.0001]. Participant follow-up
was censored because of a regimen change for 38.2%
(36.2% of NNRTI, 56.8% of protease inhibitor and
20.4% of INSTI); at 6 months after the last clinic date for
21.1% (24.2% of NNRTI, 18.1% of protease inhibitor,
18.9% of INSTI); at death for 0.9% of the cohort (0.6% of
NNRTI, 1.1% of protease inhibitor, 1.2% of INSTI) and
at the end of the study period for 39.9% (39.1% of
NNRTI, 24.0% of protease inhibitor, 59.5% of INSTI), P
less than 0.0001. Overall, 13.6% (1717/12 585) of the
cohort were deemed lost to follow-up, (16.0% of
NNRTI, 12.5% of protease inhibitor and 10.8% of
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Fig. 1. Study flow chart showing selection of eligible parti-
cipants from the UK CHIC study dataset.
INSTI, P< 0.0001). Figure 2 shows the time to
virological failure in the three treatment groups. In the
first year of follow-up (18 months after ART initiation)
the cumulative incidence curves had reached about 4%
for the NNRTI group, 7% for the INSTI group and 14%
for the protease inhibitor group. After 4 years of follow-
up this had increased to about 8, 12 and 24%, respectively.
(log-rank P< 0.0001). Figure 3 shows the effects of
different agents within treatment groups. The NNRTI
nevirapine had a higher cumulative incidence than
efavirenz and rilpivirine (log-rank P¼ 0.002). The older
protease inhibitor lopinavir had a higher cumulative
incidence than darunavir and atazanavir, though this was a
small group and the difference was not statistically
significant (log-rank P¼ 0.31). The three INSTI agents
had a similar virological response during the study period,
although dolutegravir and elvitegravir had shorter follow-
up times than raltegravir (log-rank P¼ 0.28).
Univariate Cox regression was used to examine the
association between other exposure variables and
virological failure. Factors with some evidence for an
association with virological failure were sex [women
more likely to experience virological failure than men:
HR 1.45, 95% confidence interval (CI) 1.20–1.73,
P< 0.0001]; ethnicity (black African and black other
groups more likely to experience virological failure than
white participants: HR 2.03, 95% CI 1.70–2.43,
P< 0.0001 and HR 2.36, 95% CI 1.83–3.03,
P< 0.0001, respectively); HIV acquisition risk group
(heterosexual and other/unknown associated with
increased virological failure compared with homosex-
ual/bisexual: HR 1.79, 95% CI 1.53–2.10, P< 0.0001
and HR 1.70, 95% CI 1.30–2.22, P< 0.0001, respec-
tively); baseline CD4þ cell count (higher CD4þ
associated with decreased virological failure: HR 0.29
95% CI 0.24–0.37, P< 0.0001 for CD4þ> 500 cells/ml
compared with CD4þ< 200 cells/ml); and baseline HIV
RNA (high viral load associated with increased
virological failure: participants with HIV RNA
100 000–1000 000 copies/ml had a HR of 2.47, 95%
CI 1.65–3.71, P< 0.0001 and those with HIV RNA
>1000 000 copies/ml had a HR of 3.54, 95% CI 2.24–
5.57, P< 0.0001, compared with those with HIV RNA
50–1000 copies/ml). There was a trend towards lower
risk of virological failure in the latter years of the study
period: HR 0.72 (95% CI 0.61–0.86, P¼ 0.0002) for the
2014/2015 period and HR 0.81 (95% CI 0.64–1.03,
P¼ 0.09) for the 2016/2017 period, compared with
2012/2013, likelihood ratio test P¼ 0.0007. There was
no significant difference between the NRTI backbones
tenofovir-emtricitabine and abacavir-lamivudine.
After adjusting for sex, ethnicity, age, HIV acquisition
risk, baseline CD4þ cell count, HIV RNA, NRTI
backbone and year of ART initiation, the INSTI and
protease inhibitor groups had a higher risk of virological
failure than the NNRTI group. INSTI compared with
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Table 1. Baseline characteristics by treatment group.
Total, n¼12 585 INSTI, n¼3193 PI, n¼3648 NNRTI, n¼5744 P valueM
Sexa, n (%)
Male 10 031 (79.7) 2651 (83.1) 2664 (73.1) 4716 (82.2) <0.0001
Female 2547 (20.3) 541 (16.9) 983 (26.9) 1023 (17.8)
Agea (years)
Mean (SD) 37 (10) 38 (10) 37 (10) 37 (10) 0.05
Ethnicity, n (%)
White 7087 (56.3) 1877 (58.8) 1984 (54.4) 3226 (56.2) <0.0001
Black African 2400 (19.1) 442 (13.8) 811 (22.2) 1147 (20.0)
Black other 720 (5.7) 174 (5.5) 238 (6.5) 308 (5.4)
Other/unknown 2378 (18.9) 700 (21.9) 615 (16.9) 1053 (18.4)
HIV acquisition risk, n (%)
Homosexual/bisexual 7534 (59.9) 2031 (63.6) 1958 (53.7) 3545 (61.7) <0.0001
Heterosexual 3754 (29.8) 793 (24.8) 1254 (34.4) 1707 (29.7)
Other/unknown 1297 (10.3) 369 (11.6) 436 (11.9) 492 (8.6)
CD4þ cell counta (cells/ml)
Median (IQR) 379 (246–537) 424 (280–588) 348 (170–510) 376 (270–520) <0.0001
HIV RNAa (copies/ml)
log10 median (IQR) 4.7 (4.1–5.2) 4.7 (4.1–5.2) 4.8 (4.2–5.4) 4.7 (4.1–5.1) <0.0001
NRTI backbone, n (%)
TDF-FTC 9537 (75.8) 1899 (59.4) 2851 (78.2) 4787 (83.3) <0.0001
ABC-3TC 2516 (20.0) 1187 (37.2) 569 (15.5) 760 (13.3)
Other 532 (4.2) 107 (3.4) 228 (6.3) 197 (3.4)
Year started ART
2012/2013 5010 (39.8) 288 (9.0) 1685 (46.2) 3037 (52.9) <0.0001
2014/2015 4943 (39.3) 1564 (49.0) 1325 (36.3) 2054 (35.7)
2016/2017 (up to 30 June 17) 2632 (20.9) 1341 (42.0) 638 (17.5) 653 (11.4)
ABC-3TC, abacavir-lamivudine; ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase
inhibitor; NRTI, nucleos(t)ide reverse transcriptase inhibitor; PI, protease inhibitor; TDF-FTC, tenofovir-emtricitabine.
aMissing data (INSTI, PI, NNRTI, total): sex (1, 1, 5, 7); age (1, 3, 7, 11); CD4þ cell count (665, 817, 1176, 2658); HIV RNA (626, 815, 1263, 2704).
MChi-square for all comparisons except mean age (ANOVA), and median CD4þ/HIV RNA (Kruskal–Wallis test).
NNRTI: adjusted HR(aHR) 1.52, 95% CI 1.19–1.95,
P¼ 0.0009 (unadjusted HR 1.36, 95% CI 1.10–1.68,
P¼ 0.004), protease inhibitor compared with NNRTI:
aHR 2.70, 95% CI 2.27–3.21, P less than 0.0001
(unadjusted HR 3.02, 95% CI 2.55–3.57, P< 0.0001),
likelihood ratio test P less than 0.0001. The intention-to-
treat analysis, in which follow-up was not censored in the
case of ART class switch, showed similar results for the
INSTI and protease inhibitor groups and a higher
cumulative incidence in the NNRTI group (INSTI
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Fig. 2. Kaplan–Meier plot showing time to virological failure, stratified by treatment group.
Fig. 3. Kaplan–Meier plots showing time to virological failure stratified by agent within each treatment group: (a) nonnucleo-
side reverse transcriptase inhibitor, (b) protease inhibitor, (c) integrase strand transfer inhibitor.
compared with NNRTI: aHR 1.18, 95% CI 0.98–1.42,
P¼ 0.09; protease inhibitor compared with NNRTI:
aHR 1.83, 95% CI 1.61–2.08, P< 0.0001). Sensitivity
analyses using different definitions of virological failure
showed that the number of events decreased as the
threshold for failure increased, but the relative effects of
treatment group were largely unchanged (Table 2).
Further sensitivity analyses stratifying by calendar period
and baseline CD4þ cell count, and also limiting follow-up
time to 18 and 24 months after starting ART did not
change the study findings.
Discussion
First-line ART regimens started between 2012 and 2017
in the United Kingdom were associated with a low risk of
virological failure overall. People receiving protease
inhibitor-containing regimens were more likely to
experience virological failure than those receiving an
INSTI-containing or NNRTI-containing regimen.
Around a quarter of the protease inhibitor group had
experienced virological failure, 4.5 years after starting
ART. INSTI regimens had a lower risk of virological
failure than protease inhibitors with about 12%
experiencing virological failure, though this was higher
than the NNRTI group at about 8%.
The treatment groups differed in many of their baseline
characteristics. Although NNRTI was the most common
class prescribed for men and women, women were more
likely to receive a protease inhibitor regimen than men,
perhaps reflecting previous concerns about the use of
efavirenz during a potential childbearing period [21].
HIV acquisition risk was also strongly associated with
treatment group, with heterosexual participants and those
in the ‘other’ category more likely to receive protease
inhibitor than homosexual or bisexual participants. This
may be partly because the heterosexual group contained
most of the female participants, but could also reflect that
IDUs in the ‘other’ category were considered to have a
higher risk of poor adherence, and so more forgiving
regimens were favoured that have higher genetic barriers
to resistance and also avoid efavirenz-associated central
nervous system effects. The small difference in baseline
CD4þ cell counts between treatment groups is likely to
reflect the trend in recent years to starting ART at earlier
stages of infection, as evidence emerged of improved
clinical outcomes and reduced transmission, which
coincided with the increased use of INSTIs [22–24].
These findings are similar to those of a US study that
analysed the factors associated with the selection of first-
line regimens from 2009 to 2012 [25]. Of 873 patients,
56% had NNRTI, 36% had protease inhibitor and 8% had
raltegravir (the only INSTI available at the time). Protease
inhibitors were more likely to be prescribed than
NNRTIs in women [odds ratio (OR) 2.5, 95% CI
1.5–4.3]; those with baseline HIV RNA more than
100 000 copies/ml (OR 1.8, 95% CI 1.3–2.5) and active
substance users (OR 1.7, 95% CI 1.2–2.5). Raltegravir
was more likely to be prescribed than NNRTIs in people
with a history of depression (OR 3.5, 95% CI 1.9–6.4);
hepatitis C or liver disease (OR 3.3, 95% CI 1.4–7.8) and
cardiovascular or cerebrovascular disease (OR 4.7, 95%
CI 1.3–17.0).
There was a change in the prescribing practice during the
current study period, with a decline in the proportion that
received NNRTIs, and an increase in the use of protease
inhibitors and INSTIs. The proportion of first-line
regimens that contained INSTI increased almost 10-fold,
following the availability of this class and its inclusion in
BHIVA first-line treatment guidelines in 2012 [1]. Overall,
38% of participants had a regimen change, and this was
more common in the protease inhibitor group and less
common in the INSTI group. This is higher than observed
in most RCTs, but similar to the rate of third agent change
of 28 per 100 person-years (95% CI 26–31) found by a
review of aggregate data from 1949 patients at eight UK
centres from 2012 to 2015 [26]. It was decided to censor
follow-up at a regimen change in the current study as this
indicated the treatment group had changed, which may
have been for economic, simplification or tolerability
reasons, rather than lack of virological effectiveness.
The INSTI group had a 1.52 times greater risk of
virological failure compared with NNRTI, even after
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Table 2. Multivariate Cox sensitivity analysis.
VF definition (copies/ml) All VF events, n (%)
INSTI group
Adjusted HRa (95% CI)
PI group
Adjusted HRa (95% CI)
Study definition
2>50 947 (7.5%) 1.52 (1.19–1.95) 2.70 (2.27–3.21)
Alternative definitions
1>50 2316 (18.4%) 1.26 (1.08–1.46) 1.90 (1.70–2.12)
1>200 1017 (8.1%) 1.28 (1.01–1.62) 2.47 (2.09–2.93)
2>200 473 (3.8%) 1.70 (1.18–2.44) 3.02 (2.33–3.90)
1>1000 636 (5.1%) 1.45 (1.07–1.97) 2.47 (1.99–3.06)
2>1000 275 (2.2%) 1.98 (1.24–3.18) 2.69 (1.93–3.74)
INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; VF, virological failure.
aHazard ratio of virological failure adjusted for age, sex, ethnicity, HIV acquisition risk group, baseline CD4þ cell count, HIV RNA, NRTI backbone
and year of ART initiation; NNRTI¼ reference group.
adjusting for other covariates. There was a more marked
difference in the protease inhibitor recipients who were
2.7 times more likely to experience virological failure.
This may be because there were other factors related to
poor adherence that were not measured or controlled for
in this analysis. Univariate analysis suggested sex,
ethnicity, HIV acquisition risk group, baseline CD4þ
cell count, viral load and year of ART initiation were all
associated with virological failure. Several other studies
have identified risk factors associated with virological
failure. Two analyses of UK CHIC data, spanning the
periods 1996–2003 and 1998–2013, found that black
ethnicity, heterosexual HIV acquisition risk group and
younger age groups were associated with increased risk of
virological failure [27,28]. The latter study also found
earlier calendar year to be a risk factor for virological
failure. The authors discussed possible reasons for the
decline in virological failure over time, including
nonadherent individuals leaving the at-risk population
as they experienced virological failure, behaviour change
to accommodate better adherence, and that viral
replication may be suppressed with lower levels of
adherence on established regimens [28]. A further analysis
of the effect of transmitted drug resistance on first-line
treatment outcomes found that those receiving protease
inhibitor regimens were 2.17 times more likely to
experience viraemia than those receiving NNRTI
regimens (95% CI 1.88–2.51, P< 0.001), with no
impact from transmitted resistance [29]. This study found
other predictors of viraemia to be injecting drug use,
black ethnicity, high baseline viral load, low CD4þ cell
count and the use of abacavir compared with tenofovir.
One of the strengths of the current study is that it uses
real-world data from a multicentre collaboration that is
likely to be representative of people living with HIV in
the United Kingdom, with findings that may be
generalizable beyond the population that is typically
recruited into randomized trials. Another advantage is
that participants could switch agents within a class
without their follow-up being censored, thus increasing
the follow-up time to examine class effects. However, as
with any observational study, our analysis may be affected
by unmeasured confounding as the choice of ART class
(and drugs within a class) for a given individual will be
determined by many factors, including (but not limited
to) information on any comorbidities present (including
mental health problems) or any concomitant medications
prescribed. This information may not be available in
observational databases and, as a result, it may be difficult
to control for these factors. Clinicians will often favour a
particular ART class depending on the clinical context,
even when following established treatment guidelines.
For example, protease inhibitor-containing regimens and
some of the newer INSTIs may be preferentially used for
individuals in whom there were concerns about
adherence due to the perceived higher genetic barrier
to resistance of these drugs. Significantly, one of the UK
CHIC contributing centres has explored the indications
for raltegravir use up to the end of 2012 in treatment-
naive patients, and these included the need for a rapid
reduction in viral load, for example during pregnancy;
concerns about drug interactions with other medication,
particularly in the context of mycobacterial coinfection;
and tolerability issues such as relative contraindications to
efavirenz use [30]. This inability to rule out potential
unmeasured confounding is the main reason why
evidence from observational studies is generally rated as
low quality for guideline development, although this
should be balanced against the benefits, particularly
related to generalizability.
Several other limitations should also be noted. In particular,
UK CHIC participants were excluded if they had an
undetectable viral load at ART initiation to avoid
misclassification of those already receiving treatment.
However, it was not possible to detect those previously
treated who then present to a participating centre as ART-
naive. It was surprising that 1912 people appeared to have
anundetectable viral load atART initiation, suggesting that
many were already receiving ART but this information was
missing from their UK CHIC record, and this group were
excluded from the study. The inclusion of the newer
INSTIs elvitegravir and dolutegravir, which were licensed
by the European Medicines Agency in Mayand November
of 2013 respectively, means that this study may inadver-
tently have included some clinical trial participants, whose
responses would be likely to differ [31]. Although likely to
have good internal validity to the UK population starting
ART between 2012 and 2017, this study may lack
generalizability to populations in other geographical
settings. The findings are probably only applicable to
high-income settings with a choice of ART agent. The
present analysis does not include data on genotypic
resistance testing; however, this will be examined in future
analyses of integrase mutations associated with exposure to
the INSTI class. Finally, although a small proportion of
participants unfortunately died after initiating ART, we did
not perform a formal competing risks analysis as the
numberof such deaths was small and findings were unlikely
to be affected greatly by this.
In the INSTI era, first-line ART regimens containing
INSTI or protease inhibitor were associated with a
greater risk of virological failure than those containing
NNRTI and adjusting for potential confounders did not
remove this effect. Poorer virological outcomes in these
groups may be related to factors associated with
suboptimal adherence that have not been captured by
this analysis. There is likely to be residual channelling bias
resulting from selected use of INSTIs and protease
inhibitors in specific clinical contexts. Furthermore, these
findings illustrate the changing clinical practice in the use
of first-line regimens in the United Kingdom and could
be used for benchmarking of virological response in
future studies.
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